Skip to main content
Part of Sickle Cell Disease on Somebody To Talk To

Sickle Cell Disease clinical trials near you

A clinical trial is a research study that tests whether a treatment is safe and works. Taking part is always your choice, and you can stop at any time. Listing a study here is not a recommendation — talk it through with your own team.

138 recruiting studiesFrom ClinicalTrials.gov (opens in a new tab)

Trial results

8 shown of 138

8 shown of 138 clinical trials.

  1. RecruitingObservationalNCT07064174

    Sickle Cell Kidney Biorepository

    Sickle Cell Trait, Sickle Cell Disease (SCD), Chronic Kidney Disease

    Kidney disease is a major cause of illness and death in people with sickle cell disease and sickle cell trait. Despite these concerning facts, we do not (1) have an in-depth understanding of how kidney disease starts in sickle cell disease and sickle cell trait, (2) have detailed insights into why kidney disease is worse in people with sickle cell disease and sickle cell trait, (3) have management options that are tailored to treating or preventing kidney disease in people with sickle cell disease or sickle cell trait. The SCeK Biorepository is a specialized, secure repository designed for the collection of blood and urine samples from people with sickle cell disease and sickle cell trait. These samples are connected to detailed medical records, with the sole purpose of allowing researchers to better understand how kidney disease starts and progresses in people with the sickle cell gene. By studying these stored samples (using new tests) together with health information, researchers can find better early warning signs of kidney injury and develop better ways to protect kidney health in people with sickle cell disease and sickle cell trait.

    Sites
    2
    Target
    800
    Study sites
    Dallas, US +1 more

    Sponsor: University of Texas Southwestern Medical Center

    View on ClinicalTrials.gov(opens in a new tab)
  2. RecruitingObservationalNCT03327428

    Sickle-cell Disease Registry of the GPOH

    Sickle Cell Disease

    Sickle cell disease is one of the most common hereditary diseases. Most severe complications can be avoided if the disease is detected early and treated appropriately. The sickle cell disease registry of the Society for Paediatric Oncology/Haematology aims at describing the epidemiology of sickle cell disease in German-speaking central Europe. Patients with sickle cell disease will be characterized clinically and genetically and treatment will be documented with the aim to find predictors of the course of disease. In addition, the registry results should provide a solid evidence base to incorporate sickle cell disease into routine newborn screening and to update the national guidelines for the management of patients suffering from sickle cell disease in Germany. A consortium of five university hospitals (Berlin, Frankfurt, Hamburg, Heidelberg, Ulm) has been mandated by the Society for Paediatric Oncology/Haematology to implement this registry. The number of participating centers is constantly increasing and new centers that take care of either pediatric or adult patients with sickle cell disease are encouraged to support the registry. For further information please refer to: http://www.sichelzellkrankheit.info/

    Sites
    1
    Target
    1,000
    Study sites
    Heidelberg, DE

    Sponsor: University Hospital Heidelberg

    View on ClinicalTrials.gov(opens in a new tab)
  3. RecruitingInterventionalNCT07442851

    SickleFit Exercise and Nutrition Study

    Sickle Cell Disease, Aging

    To goal of this study is to pilot the SickleFit exercise and nutrition intervention in adults with sickle cell disease in a randomized control trial

    Sites
    1
    Target
    40
    Study sites
    Durham, US

    Sponsor: Duke University

    View on ClinicalTrials.gov(opens in a new tab)
  4. RecruitingInterventionalNCT06035939

    SMYLS Multi-site Trial

    Sickle Cell Disease

    The purpose of this study is to find out whether a web-based intervention using a mobile app is helpful for teens and young adults with sickle cell disease (SCD) in learning how to care for and manage their symptoms.

    Sites
    1
    Target
    272
    Study sites
    Charleston, US

    Sponsor: Medical University of South Carolina

    View on ClinicalTrials.gov(opens in a new tab)
  5. RecruitingInterventionalNCT07316478

    Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease

    Sickle Cell Disease

    The purpose of this research is to determine whether a new stress management and mindfulness program can improve quality of life in individuals with sickle cell disease. The program is based on a number of empirically supported treatments including techniques from cognitive-behavioral therapy like overcoming motivational barriers to self-care, learning to see things as accurately as possible, practicing assertive communication, relaxation exercises like deep slow breathing, mindfulness meditation, and other stress management strategies.

    Sites
    1
    Target
    50
    Study sites
    Philadelphia, US

    Sponsor: University of Pennsylvania

    View on ClinicalTrials.gov(opens in a new tab)
  6. RecruitingPhase 4InterventionalNCT06526117

    Stroke Prevention in Nigeria 2 Trial

    Sickle Cell Disease, Stroke

    The primary goal of this study is to complete a multicenter single-arm, type I hybrid trial to assess the effectiveness of hydroxyurea therapy for primary stroke prevention in high-risk children with sickle cell anemia (SCA) living in Nigeria in routine care settings.

    Sites
    2
    Target
    220
    Study sites
    Kano, NG +1 more

    Sponsor: Vanderbilt University Medical Center

    View on ClinicalTrials.gov(opens in a new tab)
  7. RecruitingPhase 3InterventionalNCT07247188

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Sickle Cell Disease

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    Sites
    7
    Target
    100
    Study sites
    Atlanta, US +6 more

    Sponsor: Sanofi

    View on ClinicalTrials.gov(opens in a new tab)
  8. RecruitingPhase 2InterventionalNCT03121001

    Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

    Sickle Cell Disease

    The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT). The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.

    Sites
    1
    Target
    50
    Study sites
    Chicago, US

    Sponsor: University of Illinois at Chicago

    View on ClinicalTrials.gov(opens in a new tab)